Nasus Pharma (NSRX) Fundamental Analysis: Revenue, Earnings & Valuation

0.94 / 10

Underperform

Fundamental measurement shows concerning quality (0.9/10). Key metrics: Interest coverage ratio (EBIT / Interest expense) (%) is 27.58, ranking in quartile 1 with a quality score of 2; Days sales outstanding is 338.23, ranking in group 2 with a quality score of 1/3; Total operating revenue YoY growth is 294.17%, ranking in group 2 with a score of 2. Overall, the fundamental picture is weak, supporting a cautious stance.

Analysis Checks(3/4)

Total operating revenue (YoY growth rate %)

Value294.17

Score2/3

Weight-119.73%

1M Return1.11%

Days sales outstanding

Value338.23

Score1/3

Weight154.05%

1M Return-1.57%

Interest coverage ratio (EBIT / Interest expense) (%)

Value27.58

Score2/3

Weight111.81%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value392.33

Score2/3

Weight-46.13%

1M Return0.43%

Is NSRX fundamentally strong?

NSRX scores 0.94/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -25.77 P/E ratio, -11.43 P/B ratio, and 0.00% earnings growth, these metrics solidify its Underperform investment rating.